journal
https://read.qxmd.com/read/37735847/continuous-glucose-monitoring-metrics-and-pregnancy-outcomes-in-insulin-treated-diabetes-a-post-hoc-analysis-of-the-glucomoms-trial
#1
JOURNAL ARTICLE
Doortje Rademaker, Anne W T van der Wel, Rik van Eekelen, Daphne N Voormolen, Harold W de Valk, Inge M Evers, Ben Willem Mol, Arie Franx, Sarah E Siegelaar, Bas B van Rijn, J Hans DeVries, Rebecca C Painter
AIM: To investigate the association between continuous glucose monitoring (CGM) metrics and perinatal outcomes in insulin-treated diabetes mellitus in pregnancy. MATERIALS AND METHODS: In a post-hoc analysis of the GlucoMOMS randomized controlled trial, we investigated the association between the metrics of an offline, intermittent CGM, glycated haemoglobin (HbA1c) and perinatal outcomes per trimester in different types of diabetes (type 1, 2 or insulin-treated gestational diabetes mellitus [GDM])...
September 21, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37735841/pharmacokinetic-and-pharmacodynamic-bioequivalence-of-gan-lee-insulin-analogues-aspart-rapilin%C3%A2-lispro-prandilin%C3%A2-and-glargine-basalin%C3%A2-with-eu-und-us-sourced-reference-insulins
#2
JOURNAL ARTICLE
Wei Chen, Jia Lu, Leona Plum-Mörschel, Grit Andersen, Eric Zijlstra, Anshun He, Tian Xie, Longling Li, Chunyue Hao, Zhongru Gan, Tim Heise
AIM: For the successful approval and clinical prescription of insulin biosimilars, it is essential to show pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence to the respective reference products sourced from the European Union and the United States. METHODS: Three phase 1, randomized, double-blind, three-period crossover trials compared single doses of the proposed biosimilar insulin analogues aspart (GL-Asp, n = 36), lispro (GL-Lis, n = 38) and glargine (GL-Gla, n = 113), all manufactured by Gan & Lee pharmaceuticals, to the respective EU- and US-reference products in healthy male participants (GL-Asp and GL-Lis) or people with type 1 diabetes (GL-Gla)...
September 21, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37735822/risk-of-thyroid-cancer-associated-with-glucagon-like-peptide-1-receptor-agonists-and-dipeptidyl-peptidase-4-inhibitors-in-patients-with-type-2-diabetes-a-population-based-cohort-study
#3
JOURNAL ARTICLE
Sungho Bea, Heejun Son, Jae Hyun Bae, Sun Wook Cho, Ju-Young Shin, Young Min Cho
AIMS: To determine the potential association between the use of either glucagon-like peptide-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase-4 (DPP-4) inhibitors, and the risk of thyroid cancer in individuals with type 2 diabetes. MATERIALS AND METHODS: This population-based cohort study used claims data from the Korean National Health Insurance Database, 2014-2020. Two distinct cohorts were established to compare each incretin-based drug with sodium-glucose cotransporter-2 (SGLT2) inhibitors, chosen as active comparators because of their previous non-association with thyroid cancer, and their common usage as add-on therapy to metformin along with GLP-1RAs and DPP-4 inhibitors...
September 21, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37735816/long-term-effects-of-coronavirus-disease-2019-on-diabetes-complications-and-mortality-in-people-with-diabetes-two-cohorts-in-the-uk-and-hong-kong
#4
JOURNAL ARTICLE
Eric Yuk Fai Wan, Sukriti Mathur, Ran Zhang, Athene Hoi Ying Lam, Boyuan Wang, Vincent Ka Chun Yan, Celine Sze Ling Chui, Xue Li, Carlos King Ho Wong, Francisco Tsz Tsun Lai, Ching Lung Cheung, Esther Wai Yin Chan, Kathryn Choon Beng Tan, Ian Chi Kei Wong
AIM: To evaluate the long-term associations between coronavirus disease 2019 (COVID-19) and diabetes complications and mortality, in patients with diabetes. MATERIALS AND METHODS: People with diabetes diagnosed with COVID-19 infection (exposed group), from 16 March 2020 to 31 May 2021 from the UK Biobank (UKB cohort; n = 2456), and from 1 April 2020 to 31 May 2022 from the electronic health records in Hong Kong (HK cohort; n = 80 546), were recruited...
September 21, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37732487/efficacy-and-safety-of-adding-once-weekly-dulaglutide-to-basal-insulin-for-inadequately-controlled-type-2-diabetes-in-chinese-patients-award-chn3-a-randomized-double-blind-placebo-controlled-phase-iii-trial
#5
JOURNAL ARTICLE
Weimin Wang, Xin Yan, Zhifeng Cheng, Qiqi Zhang, Rui Wang, Yuying Deng, Jianhua Ma, Dalong Zhu
AIM: To determine the efficacy and safety of once-weekly dulaglutide added to basal insulin in Chinese patients with type 2 diabetes mellitus (T2DM) with inadequate glycaemic control. MATERIALS AND METHODS: In the phase III, double-blind AWARD-CHN3 study, Chinese patients with T2DM (N = 291) and glycated haemoglobin (HbA1c) ≥7.0% and ≤11.0% receiving stable doses of basal insulin glargine with metformin and/or acarbose were randomized (1:1) to receive add-on dulaglutide 1...
September 21, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37732476/longitudinal-association-of-continuous-glucose-monitoring-derived-metrics-with-cognitive-decline-in-older-adults-with-type-2-diabetes-a-1-year-prospective-observational-study
#6
LETTER
Taiki Sugimoto, Haruhiko Tokuda, Hisayuki Miura, Shuji Kawashima, Takuya Omura, Takafumi Ando, Yujiro Kuroda, Nanae Matsumoto, Kosuke Fujita, Kazuaki Uchida, Yoshinobu Kishino, Takashi Sakurai
No abstract text is available yet for this article.
September 21, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37726978/telehealth-use-and-its-impact-on-clinical-outcomes-in-patients-with-type-2-diabetes-during-the-covid-19-pandemic
#7
JOURNAL ARTICLE
Yixue Shao, Lizheng Shi, Elizabeth Nauman, Eboni Price-Haywood, Charles Stoecker
AIM: To evaluate the impact of telehealth use during the COVID-19 pandemic on glycaemic control and other clinical outcomes among patients with type 2 diabetes. METHODS: We used electronic health records from the Research Action for Health Network (REACHnet) database for patients with type 2 diabetes who had telehealth visits and those who only received in-person care during the pandemic. A quasi-experimental method of difference-in-difference with propensity-score weighting was implemented to mitigate selection bias and to control for observed factors related to telehealth use...
September 19, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37726973/role-of-the-tripartite-motif-containing-trim-family-of-proteins-in-insulin-resistance-and-related-disorders
#8
REVIEW
Jianrong Chen, Xianjie Feng, Xu Zhou, Yong Li
Emerging evidence suggests that the ubiquitin-mediated degradation of insulin-signalling-related proteins may be involved in the development of insulin resistance and its related disorders. Tripartite motif-containing (TRIM) proteins, a superfamily belonging to the E3 ubiquitin ligases, are capable of controlling protein levels and function by ubiquitination, which is essential for the modulation of insulin sensitivity. Recent research has indicated that some of these TRIMs act as key regulatory factors of metabolic disorders such as type 2 diabetes mellitus, obesity, nonalcoholic fatty liver disease, and atherosclerosis...
September 19, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37724708/the-effect-of-empagliflozin-and-fenofibrate-therapies-alone-and-in-combination-on-the-serum-urate-concentration-in-hyperuricaemic-type-2-diabetes
#9
LETTER
Timothy M E Davis, Sharon Maxwell, Cathy Chan, Helen I Keen, Wendy A Davis
No abstract text is available yet for this article.
September 19, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37724698/a-randomized-double-blind-placebo-controlled-phase-3-trial-to-evaluate-the-efficacy-and-safety-of-cetagliptin-added-to-ongoing-metformin-therapy-in-patients-with-uncontrolled-type-2-diabetes-with-metformin-monotherapy
#10
JOURNAL ARTICLE
Linong Ji, Jinmiao Lu, Leili Gao, Xiaoguang Yan, Jifang Li, Zhifeng Cheng, Lili Zhang, Junhang Tian, Ping Li, Jie Bai, Daosheng Xie, Jiahong Zhao, Juping Ding, Qiang Yu, Tong Wang
AIM: This trial was designed to assess the efficacy and safety of cetagliptin added to metformin in Chinese patients with type 2 diabetes who had inadequate glycaemic control with metformin monotherapy. METHODS: In total, 446 patients with type 2 diabetes on metformin monotherapy were randomized to receive the addition of once-daily cetagliptin 100 mg, cetagliptin 50 mg and placebo in a 2:2:1 ratio for 24-week double-blind treatment. At week 24, patients initially randomized to cetagliptin 50 mg and placebo were switched to cetagliptin 100 mg for 28 weeks open-label treatment...
September 19, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722974/daily-unstructured-physical-activity-affects-mean-glucose-occurrence-of-hypoglycaemia-and-glucose-variability-in-people-with-type-1-diabetes
#11
LETTER
Linda C A Drenthen, Mandala Ajie, Esmée A Bakker, Evertine J Abbink, Dick H J Thijssen, Cees J Tack, Bastiaan E de Galan
No abstract text is available yet for this article.
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722973/glycaemic-control-and-weight-outcomes-after-adding-or-switching-to-biphasic-insulin-aspart-30-70-in-people-with-type-2-diabetes-mellitus-previously-treated-with-basal-bolus-insulin-in-uk-clinical-practice
#12
LETTER
Melanie J Davies, Amra Ciric Alibegovic, Pranav Kelkar, Uffe Christian Braae, Anders Boeck Jensen
No abstract text is available yet for this article.
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722968/diabetes-foot-complications-and-standardized-mortality-rate-in-type-2-diabetes
#13
JOURNAL ARTICLE
Mike Stedman, Adam Robinson, George Dunn, Bernado Meza-Torres, J Martin Gibson, Neil D Reeves, Edward B Jude, Michael Feher, Gerry Rayman, Martin B Whyte, Michael Edmonds, Adrian H Heald
AIM: To quantify the impact of foot complications on mortality outcomes in people with type 2 diabetes (T2D), and how routinely measured factors might modulate that risk. MATERIALS AND METHODS: Data for individuals with T2D for 2010-2020, from the Salford Integrated Care Record (Salford, UK), were extracted for laboratory and clinical data, and deaths. Annual expected deaths were taken from Office of National Statistics mortality data. An index of multiple deprivation (IMD) adjusted the standardized mortality ratio (SMR_IMD)...
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722966/albuminuria-lowering-effect-of-adding-semaglutide-on-top-of-empagliflozin-in-individuals-with-type-2-diabetes-a-randomized-and-placebo-controlled-study
#14
JOURNAL ARTICLE
Suvanjaa Sivalingam, Victor Soendergaard Wasehuus, Viktor Rotbain Curovic, Martin Baek Blond, Tine W Hansen, Frederik Persson, Peter Rossing
AIM: To investigate whether combined treatment with empagliflozin (a sodium-glucose cotransporter-2 inhibitor) and semaglutide (a glucagon-like peptide-1 receptor agonist) can reduce urinary albumin-creatinine ratio (UACR) compared to treatment with empagliflozin alone in individuals with type 2 diabetes (T2D) and albuminuria. METHODS: We conducted a randomized, placebo-controlled, double-blind, parallel study including 60 individuals with T2D and albuminuria. All participants initiated open-label empagliflozin 25 mg once daily, on top of renin-angiotensin system inhibition, in a run-in period of 26 weeks...
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722965/human-placenta-derived-mesenchymal-stem-cells-ameliorate-diabetic-kidney-disease-by-modulating-the-t-helper-17-cell-regulatory-t-cell-balance-through-the-programmed-death-1-programmed-death-ligand-1-pathway
#15
JOURNAL ARTICLE
Jiao Wang, Honghong Liu, Guanru Yue, Yuanyuan Deng, Wei Cai, Jixiong Xu
AIM: To investigate the therapeutic effects and immunomodulatory mechanisms of human placenta-derived mesenchymal stem cells (PMSCs) in diabetic kidney disease (DKD). METHODS: Streptozotocin-induced DKD rats were administered an equivalent volume of saline or PMSCs (1 × 106 in 2 mL phosphate-buffered saline per rat) for 3 weeks. Eight weeks after treatment, we examined the biochemical parameters in the blood and urine, the ratio of T helper 17 cells (Th17) and regulatory T cells (Treg) in the blood, cytokine levels in the kidney and blood, and renal histopathological changes...
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722963/time-in-range-in-patients-with-type-2-diabetes-who-are-long-term-users-of-d-nav%C3%A2-an-artificial-intelligence-driven-technology-for-autonomous-titration-of-insulin-dosing
#16
LETTER
Kevin J Williams, Eran Bashan, Caitlin Kruse, Sajitha Sritharan, Israel Hodish
No abstract text is available yet for this article.
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37722962/derivation-and-independent-validation-of-kidneyintelx-dkd-a-prognostic-test-for-the-assessment-of-diabetic-kidney-disease-progression
#17
JOURNAL ARTICLE
Girish N Nadkarni, Sharon Stapleton, Dipti Takale, Katherine Edwards, Kara Moran, Gohar Mosoyan, Michael K Hansen, Michael J Donovan, Hiddo J L Heerspink, Fergus Fleming, Steven G Coca
AIMS: To develop and validate an updated version of KidneyIntelX (kidneyintelX.dkd) to stratify patients for risk of progression of diabetic kidney disease (DKD) stages 1 to 3, to simplify the test for clinical adoption and support an application to the US Food and Drug Administration regulatory pathway. METHODS: We used plasma biomarkers and clinical data from the Penn Medicine Biobank (PMBB) for training, and independent cohorts (BioMe and CANVAS) for validation...
September 18, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37718554/intermittently-scanned-continuous-glucose-monitoring-and-hypoglycaemia-awareness-in-drivers-with-diabetes-insights-from-the-association-of-british-clinical-diabetologists-nationwide-audit
#18
JOURNAL ARTICLE
Charlotte Mark-Wagstaff, Harshal Deshmukh, Emma G Wilmot, Neil Walker, Dennis Barnes, Vernon Parfitt, Simon Saunders, Rob Gregory, Pratik Choudhary, Jane Patmore, Chris Walton, Robert E J Ryder, Thozhukat Sathyapalan
AIM: Frequent hypoglycaemia results in disruption to usual hypoglycaemic autonomic responses leading to impaired awareness of hypoglycaemia, which is associated with an increased risk of severe hypoglycaemia requiring third-party assistance (SH). The UK Driving and Vehicle Licensing Agency (DVLA) does not permit car driving if they have either a complete loss of hypoglycaemia awareness or more than one SH event a year. METHODS: The FreeStyle Libre (FSL) Association of British Clinical Diabetologists (ABCD) Nationwide Audit consists of data collected by clinicians during routine clinical work, submitted into a secure web-based tool held within the National Health Service (NHS) N3 network...
September 17, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37712754/the-real-world-observational-prospective-study-of-health-outcomes-with-dulaglutide-and-liraglutide-in-type-2-diabetes-patients-trophies-final-patient-reported-outcomes-at-24-months
#19
JOURNAL ARTICLE
Kristina S Boye, Jérémie Lebrec, Anne Dib, Elke Heitmann, Marco Orsini Federici, Maria Yu, Hélène Sapin, Annabel Barrett, Bruno Guerci, Francesco Giorgino, Martin Füchtenbusch, Luis-Emilio García-Pérez
AIM: To report health-related patient-reported outcomes (PROs) in people with type 2 diabetes (T2D) initiating their first injectable glucose-lowering medication (GLM) with two commonly prescribed glucagon-like peptide-1 receptor agonists (GLP-1RAs) from the prospective, observational TROPHIES study (The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type 2 Diabetes Patients). MATERIALS AND METHODS: TROPHIES was a two-cohort, 24-month study conducted in France, Germany and Italy...
September 15, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/37700692/severe-level-3-hypoglycaemia-occurrence-in-a-real-world-cohort-of-adults-with-type-1-or-2-diabetes-mellitus-inphorm-united-states
#20
JOURNAL ARTICLE
Alexandria Ratzki-Leewing, Jason E Black, Anna R Kahkoska, Bridget L Ryan, Guangyong Zou, Neil Klar, Kristina Timcevska, Stewart B Harris
AIMS: Among adults with insulin- and/or secretagogue-treated diabetes in the United States, very little is known about the real-world descriptive epidemiology of iatrogenic severe (level 3) hypoglycaemia. Addressing this gap, we collected primary, longitudinal data to quantify the absolute frequency of events as well as incidence rates and proportions. MATERIALS AND METHODS: iNPHORM is a US-wide, 12-month ambidirectional panel survey (2020-2021). Adults with type 1 diabetes mellitus (T1DM) or insulin- and/or secretagogue-treated type 2 diabetes mellitus (T2DM) were recruited from a probability-based internet panel...
September 13, 2023: Diabetes, Obesity & Metabolism
journal
journal
34603
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.